Arvinas Inc.

Contributing Author

Recent Articles by Arvinas Inc.

Jul-30	Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 ARVN GlobeNewswire
Jul-09	Arvinas Announces Retirement of Chief Executive Officer and Succession Plan ARVN GlobeNewswire
Jun-13	Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress ARVN GlobeNewswire
Jun-06	Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer ARVN GlobeNewswire
Jun-05	Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting ARVN GlobeNewswire
May-31	Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer ARVN GlobeNewswire
May-30	Arvinas to Present at Jefferies Global Healthcare Conference ARVN GlobeNewswire